

European Commission Initiative on Breast Cancer

Annual Declaration of Interests (ADoI)

Name: Roberto D'Amico

| Nature of activities | Period | Entity | Subject matter |
|---|---------------------|--|--|
| 1. Ownership or financial investments, including shares | - | - | - |
| 2. Membership of a managing body or equivalent structure | - | - | - |
| 3. Membership of another scientific advisory body | - | - | - |
| 4. Employment | 12/2005 – to now | - University of Modena and Reggio Emilia, Italy -Type: Public | Assistant professor of biostatistics (2005- 2015) Associate professor of biostatistics (2015 – to now) http://personale.unimore.it/Rubrica/Dettaglio/rdamico |
| 5. Consultancy/Advisory | - | - | - |
| 6. Influence on definition of research priorities | 2012 – to now | Cochrane Collaboration | Member of Cochrane Methods Priority Setting (http://priority.cochrane.org/meet-team) |

| Nature of activities | Period | Entity | Subject matter |
|---|---------------|---|--|
| 7. Research grants and other funding | 2016 – to now | ARISLA (Fondazione Italiana di Ricerca per la Sclerosi Laterale Amiotrofica) http://www.arisla.org | Rapamycin (Sirolimus) treatment for amyotrophic lateral sclerosis. A Randomised controlled trial. |
| | 2013 – to now | FISM (Fondazione Italiana Sclerosi Multipla) http://www.aism.it/home.aspx | Enhancing the way the research results are summarised for evidence-based use of treatments in multiple sclerosis and influencing the future research agenda http://allegati.aism.it/manager/trackdoc.asp?file=/manager/UploadFile/2/20130528_005_ricerca.pdf&open=1 |
| | 2013 – to now | Ministry of Health | Identify low-value health care interventions for patients with neurodegenerative disease of the Central Nervous System and Stroke to support disinvestment decisions |
| | 2009 – to now | 1. Emilia-Romagna Research Programme 2. Ministry of Health | Breast cancer with low risk of local recurrence: partial and accelerated radiation with three-dimensional conformal radiotherapy (3DCRT) vs standard radiotherapy after conserving surgery (phase III study) |
| | 2006 – to now | AIFA (Agenzia Italiana del Farmaco – Italian Medicines Agency) | SHORT-HER: multicentric randomised phase III trial of 2 different adjuvant chemotherapy regimens plus 3 vs 12 months of trastuzumab in HER2 positive breast cancer patients |

| Nature of activities | Period | Entity | Subject matter |
|--|------------------|---|---|
| 8. Principal investigator or investigator | 2013 – to now | FISM (Fondazione Italiana Sclerosi Multipla) http://www.aism.it/home.aspx | Principal Investigator. Enhancing the way the research results are summarised for evidence-based use of treatments in multiple sclerosis and influencing the future research agenda http://allegati.aism.it/manager/trackdoc.asp?file=/manager/UploadFile/2/20130528_005_ricerca.pdf&open=1 |
| | 2013 – to now | Ministry of Health | Investigator Identify low-value health care interventions for patients with neurodegenerative disease of the Central Nervous System and Stroke to support disinvestment decisions |
| | 2009 – to now | 1. Emilia-Romagna Research Programme 2. Ministry of Health | Investigator Breast cancer with low risk of local recurrence: partial and accelerated radiation with three-dimensional conformal radiotherapy (3DCRT) vs standard radiotherapy after conserving surgery (phase III study) |
| | 2006 – to now | AIFA (Agenzia Italiana del Farmaco – Italian Medicines Agency) | Investigator SHORT-HER: multicentric randomised phase III trial of 2 different adjuvant chemotherapy regimens plus 3 vs 12 months of trastuzumab in HER2 positive breast cancer patients |
| | 2012 – 2014 | FP7 - Health | COMET The COMET (Core Outcome Measures in Effectiveness Trials) Initiative |
| 9. Intellectual property rights (IPR) | - | - | - |
| 10. Other membership or affiliation | 05/2012 – to now | Cochrane Collaboration | Director of the Italian Cochrane Centre (www.cochrane.it) |
| 11. Interests of others | - | - | - |

| Nature of activities | Period | Entity | Subject matter |
|----------------------|--------|--------|----------------|
| 12. Other | - | - | - |

I also declare on my honour that the information disclosed in this form is true and complete to the best of my knowledge.
Should there be any change to the above information, I will promptly notify the responsible service of the Commission and complete a new DoI form including the changes.

Done at: Modena

Date: 14 December 2016

Signature:

Rheto D'Amico